Craif Inc. is at the forefront of revolutionizing cancer detection through innovative and non-invasive methods. Founded in 2018, the company’s mission is to eliminate cancer-related fatalities by developing cutting-edge liquid biopsy techniques using exosomes extracted from urine. This approach harnesses advanced nanotechnology and machine learning to facilitate the early and accurate identification of various diseases, promoting a society where individuals can live free from the threat of cancer.

Craif’s team comprises esteemed leaders and advisors with extensive expertise in oncology, engineering, and clinical research. Their collaborative efforts aim to enhance disease detection and treatment optimization, ensuring that healthcare systems can respond effectively and compassionately to patient needs. By focusing on early diagnosis, Craif endeavors to create a world where everyone can enjoy a long, healthy life, thereby advancing human well-being and contributing to global health initiatives. With their pioneering spirit, Craif Inc. is crafting a future where pain-free health screenings and timely interventions are the norm.